Sébastien Penninckx

Dr. Sébastien Penninckx

1. Radiotherapy department, Jules Bordet Institute, Rue Héger – Bordet 1, B-1000 Brussel, Belgium
+1
orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 July 2020 in Cancers
Verified
Journal Article
Open access
PDF file
Sébastien PenninckxSébastien Penninckx
Sébastien Penninckx
AHAnne-Catherine Heuskin
Anne-Catherine Heuskin
CMCarine Michiels
Carine Michiels
SLStéphane Lucas
Stéphane Lucas
Over the last decade, a growing interest in the improvement of radiation therapies has led to the development of gold-based nanomaterials as radiosensitizer. Although the radiosensitization effect was initially attributed to a dose enhancement mechanism, an increasing number of studies challenge this mechanistic hypothesis and evidence the importance of chemical and biological contributions. Despite extensive experimental validation, the debate regarding the mechanism(s) of gold nanoparticle radiosensitization is limiting its clinical translation. This article reviews the current state of knowledge by addressing how gold nanoparticles exert their radiosensitizing effects from a transdisciplinary perspective. We also discuss the current and future challenges to go towards a successful clinical translation of this promising therapeutic approach.

20 October 2020 in Physics in Medicine & Biology
Verified
Journal Article
Closed access
PDF file
Jan SchuemannJan Schuemann
Jan Schuemann
ABAlexander F Bagley
Alexander F Bagley
RBRoss Berbeco
Ross Berbeco
KBKyle Bromma
Kyle Bromma
KBKarl T Butterworth
Karl T Butterworth
SKSunil Krishnan
Sunil Krishnan
This roadmap outlines the potential roles of metallic nanoparticles (MNPs) in the field of radiation therapy. MNPs made up of a wide range of materials (from Titanium, Z = 22, to Bismuth, Z = 83) and a similarly wide spectrum of potential clinical applications, including diagnostic, therapeutic (radiation dose enhancers, hyperthermia inducers, drug delivery vehicles, vaccine adjuvants, photosensitizers, enhancers of immunotherapy) and theranostic (combining both diagnostic and therapeutic), are being fabricated and evaluated. This roadmap covers contributions from experts in these topics summarizing their view of the current status and challenges, as well as expected advancements in technology to address these challenges.

22 December 2021 in NAR Cancer
Verified
Journal Article
Open access
PDF file
Sébastien PenninckxSébastien Penninckx
Sébastien Penninckx
EPEloise Pariset
Eloise Pariset
ECEgle Cekanaviciute
Egle Cekanaviciute
Sylvain CostesSylvain Costes
Sylvain Costes
Radiation-induced foci (RIF) are nuclear puncta visualized by immunostaining of proteins that regulate DNA double-strand break (DSB) repair after exposure to ionizing radiation. RIF are a standard metric for measuring DSB formation and repair in clinical, environmental and space radiobiology. The time course and dose dependence of their formation has great potential to predict in vivo responses to ionizing radiation, predisposition to cancer and probability of adverse reactions to radiotherapy. However, increasing complexity of experimentally and therapeutically setups (charged particle, FLASH …) is associated with several confounding factors that must be taken into account when interpreting RIF values. In this review, we discuss the spatiotemporal characteristics of RIF development after irradiation, addressing the common confounding factors, including cell proliferation and foci merging. We also describe the relevant endpoints and mathematical models that enable accurate biological interpretation of RIF formation and resolution. Finally, we discuss the use of RIF as a biomarker for quantification and prediction of in vivo radiation responses, including important caveats relating to the choice of the biological endpoint and the detection method. This review intends to help scientific community design radiobiology experiments using RIF as a key metric and to provide suggestions for their biological interpretation.

27 June 2018 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
GGGéraldine Genard
Géraldine Genard
AWAnne-Catherine Wera
Anne-Catherine Wera
CHCamille Huart
Camille Huart
BCBenjamin Le Calve
Benjamin Le Calve
Sébastien PenninckxSébastien Penninckx
Sébastien Penninckx
CMCarine Michiels
Carine Michiels
Tumor-associated macrophages (TAMs) represent potential targets for anticancer treatments as these cells play critical roles in tumor progression and frequently antagonize the response to treatments. TAMs are usually associated to an M2-like phenotype, characterized by anti-inflammatory and protumoral properties. This phenotype contrasts with the M1-like macrophages, which exhibits proinflammatory, phagocytic, and antitumoral functions. As macrophages hold a high plasticity, strategies to orchestrate the reprogramming of M2-like TAMs towards a M1 antitumor phenotype offer potential therapeutic benefits. One of the most used anticancer treatments is the conventional X-ray radiotherapy (RT), but this therapy failed to reprogram TAMs towards an M1 phenotype. While protontherapy is more and more used in clinic to circumvent the side effects of conventional RT, the effects of proton irradiation on macrophages have not been investigated yet. Here we showed that M1 macrophages (THP-1 cell line) were more resistant to proton irradiation than unpolarized (M0) and M2 macrophages, which correlated with differential DNA damage detection. Moreover, proton irradiation-induced macrophage reprogramming from M2 to a mixed M1/M2 phenotype. This reprogramming required the nuclear translocation of NFκB p65 subunit as the inhibition of IκBα phosphorylation completely reverted the macrophage re-education. Altogether, the results suggest that proton irradiation promotes NFκB-mediated macrophage polarization towards M1 and opens new perspectives for macrophage targeting with charged particle therapy.

3 October 2016 in Nanotechnology
Verified
Journal Article
Closed access
PDF file
SLSha Li
Sha Li
Sébastien PenninckxSébastien Penninckx
Sébastien Penninckx
LKLinda Karmani
Linda Karmani
AHAnne-Catherine Heuskin
Anne-Catherine Heuskin
KWKassandra Watillon
Kassandra Watillon
SLStéphane Lucas
Stéphane Lucas
The development of new modalities and protocols is of major interest to improve the outcome of cancer treatment. Given the appealing physical properties of protons and the emerging evidence of biological relevance of the use of gold nanoparticles (GNPs), the radiosensitization effects of GNPs (5 or 10 nm) have been investigated in vitro in combination with a proton beam of different linear energy transfer (LET). After the incubation with GNPs for 24 h, nanoparticles were observed in the cytoplasm of A431 cells exposed to 10 nm GNPs, and in the cytoplasm as well as the nucleus of cells exposed to 5 nm GNPs. Cell uptake of 0.05 mg ml −1 of GNPs led to 0.78 pg Au/cell and 0.30 pg Au/cell after 24 h incubation for 10 and 5 nm GNPs respectively. A marked radiosensitization effect of GNPs was observed with 25 keV μ m −1 protons, but not with 10 keV μ m −1 protons. This effect was more pronounced for 10 nm GNPs than for 5 nm GNPs. By using a radical scavenger, a major role of reactive oxygen species in the amplification of the death of irradiated cell was identified. All together, these results open up novel perspectives for using high-Z metallic NPs in protontherapy.

24 January 2019 in Nanomedicine
Verified
Journal Article
Closed access
SLSha Li
Sha Li
SBSandra Bouchy
Sandra Bouchy
Sébastien PenninckxSébastien Penninckx
Sébastien Penninckx
RMRiccardo Marega
Riccardo Marega
OFOrnella Fichera
Ornella Fichera
SLStéphane Lucas
Stéphane Lucas
This study aimed at developing antibody-functionalized gold nanoparticles (AuNPs) to selectively target cancer cells and probing their potential radiosensitizing effects under proton irradiation. AuNPs were conjugated with cetuximab (Ctxb-AuNPs). Ctxb-AuNP uptake was evaluated by transmission electron microscopy and atomic absorption spectroscopy. Radioenhancing effect was assessed using conventional clonogenic assay. Ctxb-AuNPs specifically bound to and accumulated in EGFR-overexpressing A431 cells, compared with EGFR-negative MDA-MB-453 cells. Ctxb-AuNPs enhanced the effect of proton irradiation in A431 cells but not in MDA-MB-453 cells. These data indicate, for the first time, that combining enhanced uptake by specific targeting and radioenhancing effect, using conjugated AuNPs, is a promising strategy to increase cell killing by protontherapy.